The Human Gene Mutation Database (HGMD®) Professional has over 456,000 inherited disease-relevant mutations and polymorphisms–nearly 55% more than in the public version. In 2022 alone, HGMD Professional added nearly 46,000 new mutation entries, which won't be available in the public version until 2025.
Only with HGMD Professional can you:
But that's not it. Check out the table below for a full comparison of HGMD Public vs. HGMD Pro.
| Feature | HGMD Public | HGMD Pro |
|---|---|---|
| Up-to-date content | ||
| Displays mutations 3 years or older | X | |
| Updates mutations every 3 months | X | |
| Search features | ||
| Search by gene symbol | X | X |
| Search by gene description | X | X |
| Search by OMIM number | X | X |
| Search by disease/phenotype | X | X |
| Search missense/nonsense variants | X | X |
| Search splice mutations | X | X |
| Search regulatory mutations | X | X |
| Search small deletions | X | X |
| Search small indels | X | X |
| Search gross deletions | X | X |
| Search gross insertions | X | X |
| Search complex rearrangements | X | X |
| Search repeat variations | X | X |
| Search by chromosomal location | X | |
| Search by HGNC/OMIM/GDB/Entrez ID | X | |
| Search by RefSeq transcript | X | |
| Search by gene ontology | X | |
| Search using operators (+,-,*,"") | X | |
| Search phenotype using UMLS semantic | X | |
| Search phenotype using HGMD phenotype | X | |
| Search references by first author | X | |
| Search references by PubMed journal | X | |
| Search references by PubMed ID | X | |
| Search references by publication year | X | |
| Search references by HGMD gene | X | |
| Search references by Medline journal abbreviation | X | |
| Batch search | X | |
| Advanced search (by substitution, motif, function,etc.) | X | |
| Display features | ||
| HGMD accession ID | X | X |
| Codon change | X | X |
| Amino acid change | X | X |
| Codon number | X | X |
| Associated phenotype | X | X |
| References | X | X |
| Misense/nonsense mutations | X | X |
| Splicing mutations | X | X |
| Regulatory mutations | X | X |
| Small deletions | X | X |
| Small insertions | X | X |
| Gross deletions | X | X |
| Gross insertions/duplications | X | X |
| Complex rearrangements | X | X |
| Repeat variations | X | X |
| cDNA sequence | X | X |
| Extended cDNA | X | |
| Mutation's first published report | X | |
| Related genes | X | |
| Gene ontology | X | |
| Variant class (DM, DM?, FP, DP, DFP) | X | |
| Gene aliases | X | |
| Mutation sorted by location | X | |
| Mutation sorted by phenotype | X | |
| Mutation sorted by author | X | |
| Mutation sorted by year | X | |
| Mutation sorted by entrydate | X | |
| Extra information (HGVS, VCF, rankscore, etc.) | X | |
| Comparison between hg19 and hg38 | X | |
| Amino acid comparison | X | |
| dbNSFP predictions (CADD, MutationTaster, SIFT, Polyphen, etc. | X | |
| Orthologous amino acid conservation comparison | X | |
If you're using the public version of HGMD, your data is 3 years behind. The HGMD Professional trial is 100% FREE and has ZERO commitment. The world's largest database of inherited human mutations is just a few clicks away.
Request your free trial of HGMD Professional today.
Request Free Trial
The fall 2023 release of the Human Gene Mutation Database (HGMD) Professional is now available, adding 12,617 new entries to the world's largest collection of human inherited disease mutations. In total, HGMD Pro 2023.3 now contains 456,702 expert-curated mutations.
Four times a year, the Institute of Medical Genetics at Cardiff University releases new updates to its market-leading database, ensuring that clinical geneticists always have access to the most current and comprehensive collection of expert-curated germline mutations. This, in turn, safeguards patients from misinterpretations and misdiagnoses.
In our most recent white paper, we share a real-life story that underscores the critical importance of precision and accuracy in clinical diagnostics. The case revolves around a 2-year-old experiencing seizures and muscle twitches whose family experienced deep emotional turbulence after her diagnostic Whole Exome Sequencing (WES) test was misinterpreted. If you'd like to explore the case further and understand how HGMD Professional could have could have played a pivotal role, we invite you to read the complete white paper here.
HGMD Professional is powered by a team of expert curators at Cardiff University. Data are collected weekly by a combination of manual and computerized search procedures. In excess of 250 journals are scanned for articles describing germline mutations causing human genetic disease. The required data are extracted from the original articles and augmented with the necessary supporting data.
The number of disease-associated germline mutations published per year has more than doubled in the past decade (Figure 1). As rare and novel genetic mutations continue to be uncovered, having access to the latest scientific evidence is critical for timely interpretations of NGS data.
Figure 1. Mutation entries in HGMD Professional 2023.3. The number of inherited disease-associated germline mutations published per year has more than doubled since 2010 (within 10 years).
View the complete HGMD Professional 2023.3 statistics, below.
Unlike new machine learning or artificial intelligence platforms that rapidly index millions of journal articles for mutations, HGMD Professional leverages human judgement and expertise—every catalogued mutation has been “touched” by a trained scientist to ensure accuracy, relevance, and context.
Learn more about the industry-leading database here, where you can explore features, watch videos, and request a complimentary 5-day trial.
The summer 2023 release of HGMD Professional is now available—and with 33,342 new entries in just 3 months, it's an impressive expansion of the world's largest collection of human inherited disease mutations. In total, HGMD Pro 2023.2 now contains 444,085 entries.
For over 30 years, HGMD Professional has been used worldwide by researchers, clinicians, diagnostic laboratories and genetic counselors as an essential tool for the annotation of next-generation sequencing (NGS) data in routine clinical and translational research. Founded and maintained by the Institute of Medical Genetics at Cardiff University, HGMD Professional provides users with a unique resource containing expert-curated mutations all backed by peer-reviewed publications where there is evidence of clinical impact.
HGMD Professional is powered by a team of expert curators at Cardiff University. Data are collected weekly by a combination of manual and computerized search procedures. In excess of 250 journals are scanned for articles describing germline mutations causing human genetic disease. The required data are extracted from the original articles and augmented with the necessary supporting data.
The number of disease-associated germline mutations published per year has more than doubled in the past decade (Figure 1). As rare and novel genetic mutations continue to be uncovered, having access to the latest scientific evidence is critical for timely interpretations of NGS data.
Figure 1. Mutation entries in HGMD Professional 2023.2. The number of inherited disease-associated germline mutations published per year has more than doubled since 2010 (within 10 years).
View the complete HGMD Professional 2023.2 statistics, below.
Unlike new machine learning or artificial intelligence platforms that rapidly index millions of journal articles for mutations, HGMD Professional leverages human judgement and expertise—every catalogued mutation has been “touched” by a trained scientist to ensure accuracy, relevance, and context.
Learn more about the industry-leading database here, where you can explore features, watch videos, and request a complimentary 5-day trial.
Rare Disease Day 2023 is February 28. It’s a day to raise awareness for the more than 475 million people living with over 7,000 rare diseases globally (1). In fact, rare diseases affect 10 percent of the world’s population (1). But despite their prevalence, rare diseases present significant challenges across the patient journey.
Diagnosis of rare diseases can often take five to seven years. Symptoms can be confusing; local institutions may not have the experience or infrastructure to make a timely diagnosis; and insufficient knowledge about the disease can hinder investigations. The long road to diagnosis presents one of the greatest challenges affecting the health, survival, well-being, and the very identity of people affected by a rare disease and their families.
Delays in diagnosis can lead to inappropriate disease management and disease progression. Patients are often misdiagnosed when symptoms present similar to another disease, and a misdiagnosis can lead to unsuitable interventions. For children with a rare disease, shortening the average five- to seven-year diagnostic journey could be a matter of life or death.
At QIAGEN Digital Insights, we are advancing and accelerating the diagnosis of rare and inherited diseases. For 25 years, we have been building the world’s largest, manually curated knowledge base of genomic data. Combined with our sophisticated bioinformatics solutions and standalone genomic databases, the QIAGEN Knowledge Base ensures clinicians, researchers, and pharmaceutical companies have access to the technology and data needed to make a timely, accurate diagnosis.
In this article, we discuss the challenges of diagnosing rare diseases, the impact of misdiagnoses, and how QIAGEN Digital Insights is helping to end the diagnostic odyssey.
A disease is considered rare when it affects a relatively small number of people. In the United States, rare disease (also known as orphan diseases) are defined as any disease affecting less than 200,000 people (2). Approximately 70 percent of all rare diseases are genetic in origin. And 72 percent of genetic rare disease present at birth or in childhood (2).
Rare diseases are difficult to diagnose. As a result, many patients with rare disease enter into a diagnostic odyssey. A diagnostic odyssey is the journey that a patient with a rare disease undergoes to receive an accurate diagnosis.
As we mentioned previously, diagnostic odysseys can be extremely long, often taking five to seven years. These journeys are frustrating, emotionally draining, and financially burdensome. Patients typically see multiple providers, undergo extensive testing, and receive several misdiagnoses.
At the end of the day, diagnosing rare diseases requires a multidisciplinary approach. The diagnostic odyssey involves healthcare and biotech companies, healthcare providers, researchers, and patient advocacy groups. By increasing awareness and knowledge, improving access to diagnostic tools, and investing in research and development of new treatments, we can shorten time to diagnosis from years to mere hours.
Misdiagnosis or delayed diagnosis of a rare disease can significantly impact the patient’s health, quality of life, and financial stability. Patients may undergo unnecessary treatments, suffer side effects from inappropriate medications, experience worsening conditions, and can lose their life. In addition, the emotional and financial burdens of a misdiagnosis can strain patients and their families.
QIAGEN Digital Insights’ mission is to advance molecular intelligence from bench to bedside. With a superior quality knowledge base powered by augmented molecular intelligence (AMI) and a comprehensive portfolio of bioinformatic software, services, and specialty genomic databases, we empower clinicians, researchers, and pharmaceutical companies to accelerate the integration of genomic data into decision-making.
Our sophisticated bioinformatics tools and unrivalled knowledge enable rapid and reliable diagnosis for patients with rare diseases. We collaborate with and support some of the most prestigious healthcare and research institutions in the world, including multiple national and multi-national consortiums focused on the diagnosis of inherited and rare diseases. To date, our clinical decision support software platform, QIAGEN Clinical Insights (QCI), has been used to interpret more than 3 million patient molecular profiles for hereditary and oncology diseases.
The diagnostic odyssey for patients with rare genetic diseases can be long and heartbreaking. But at QIAGEN Digital Insights, we are working hard to discover their genetic roots and characterize thousands of potential disease-causing variants to help generate diagnoses and new disease-related gene discoveries. Driven by our ability to give life-changing answers to patients, doctors, and researchers, we are ending the diagnostic odyssey of rare diseases one gene at a time.
The Fall 2021 Release of the Human Gene Mutation Database (HGMD) Professional is now available, expanding the world’s largest collection of human inherited disease mutations to 344,012 entries–that’s 20,351 more than the previous release.
For over 30 years, HGMD Professional has been used worldwide by researchers, clinicians, diagnostic laboratories and genetic counselors as an essential tool for the annotation of next-generation sequencing (NGS) data in routine clinical and translational research. Founded and maintained by the Institute of Medical Genetics at Cardiff University, HGMD Professional provides users with a unique resource containing expert-curated mutations all backed by peer-reviewed publications where there is evidence of clinical impact.
Whether searching for an overview of known mutations associated with a particular disease, interpreting clinical test results, looking for the likely causal mutation in a list of variants, or seeking to integrate mutation content into your custom NGS pipeline or data repository—HGMD is the defacto-standard repository for heritable mutations that can be adapted to a broad range of applications.
detailed mutation reports
new mutation entries in 2020 alone
summary reports listing all known
inherited disease mutations
HGMD is powered by a team of expert curators at Cardiff University. Data are collected weekly by a combination of manual and computerized search procedures. In excess of 250 journals are scanned for articles describing germline mutations causing human genetic disease. The required data are extracted from the original articles and augmented with the necessary supporting data.
The number of disease-associated germline mutations published per year has more than doubled in the past decade (Figure 1). As rare and novel genetic mutations continue to be uncovered, having access to the latest scientific evidence is critical for timely interpretations of next-generation sequencing (NGS) data.
View the complete HGMD Professional statistics here.
Join us for a webinar on October, 21, 2021, as our experts will show you how HGMD Professional simplifies and streamlines variant classification in hereditary workflows.
Read more about the importance of having access to the most up-to-date and comprehensive database for human disease mutations in our white paper.
HGMD Professional helps clinical testing labs analyze and annotate next-generation sequencing (NGS) data with current and trusted information. Unlike other mutation databases, HGMD mutations are all backed by peer-reviewed publications where there is evidence of clinical impact.
To get the most out of your HGMD Professional subscription, visit our Resources webpage for case studies, technical notes, and video tutorials.
When a family has a child with a rare undiagnosed condition, a woman is diagnosed with an aggressive form of breast cancer, or a couple is planning their next chapter, they want assurance that the diagnostic labs that are analyzing and interpreting their genetic tests are using reputable, trusted, and up-to-date resources. That's why LabCorp, Genomics England, and other national reference laboratories use the Human Gene Mutation Database (HGMD) Professional.
The largest, expert-curated resource for finding disease-causing mutations, HGMD Professional gives diagnostic labs conducting germline NGS testing the best possible chance of confidently reaching a diagnosis.
Unlike new machine learning or artificial intelligence platforms that rapidly index millions of journal articles for mutations, HGMD Professional leverages human judgement and expertise—every catalogued mutation has been “touched” by a trained scientist to ensure accuracy, relevance, and context. Therefore, HGMD Professional does not contain erroneous information or include inferred genotypes (based on documented protein alterations) or inferred protein alterations (based on documented genotypes). It is the most trusted starting resource for answering the question, “Does this mutation cause human disease?”
“Next-generation sequencing has become a powerful tool to identify genetic variants that play a role in inherited diseases, providing a flexible technology platform that allows us to go from large-scale to highly targeted test panels that can be used for both clinical diagnostics and in studies of new therapies and diagnostics,” said Marcia Eisenberg, PhD and Chief Scientific Officer for LabCorp Diagnostics. “Having access to the most comprehensive and up-to-date catalogue of known mutations augments our existing variant classification expertise. This will allow us to continue to provide physicians and researchers with the best possible test interpretations, advancing LabCorp’s mission to improve health and improve lives.” Read the official press release here.
HGMD Professional is unique in that it not only catalogs disease-causing mutations in a centralized, easy-to-search database, it also provides users with detailed information about each mutation. For example, HGMD Professional provides information on genotype-phenotype relationships, literature references, HGVS descriptions, genomic coordinates, and, more recently, nucleotide-level annotations. This level of detail is not supported by AI-powered databases.
Thousands of clinical labs use HGMD Professional as an important resource for their informatics pipeline. For example, in addition to LabCorp, Genomics England uses HGMD Professional in 13 NHS Genomic Medicine Centres to aid in the analysis and interpretation of NGS tests for rare, inherited diseases.
Today with the advent of digitalization, there are a number of "comprehensive genomic search engines" that tout artificial intelligence as the best way to identify and interpret pathogenic variants from large quantities of data. However, artificial intelligence does not compare or replace human judgment.
| Feature | Expert Curation | Artificial Intelligence |
|---|---|---|
| Speed of curation | X | XXX |
| Quality of data | XXX | X |
| Reduced noise in data | XXX | X |
| Identification of published errors | XXX | n/a |
| Normalize to gene model (needed to compare mutations from different sources) | XXX | n/a |
| Minimize artifact mutations | XXX | n/a |
| Re-classify mutations | XXX | n/a |
X = low | XXX = high | n/a = not capable
In clinical diagnostic settings, labs cannot afford to misinterpret a mutation. While AI-powered databases offer greater curation speeds, they do so at a price: they only index articles (oftentimes just the abstracts), they do not re-classify mutations are more information comes to light, they have no way of reconciling discrepancies in variant reporting.
HGMD curators note that approximately 20% of articles have discrepancies in variant reporting that require additional scrutiny. Of these, 25% can be resolved by utilizing other information reported in the manuscript or by referring to supplementary material. However, about 75% of these ambiguities necessitate direct contact with the authors [1]. The HGMD curation team does contact authors directly if they encounter discrepancies in variant reports. AI-powered solutions do not offer this feature.
Want to try HGMD Professional in your lab? It's easy and free! Simply fill out this form and one of our experts will get you set-up with HGMD Professional in your lab for up to 5 days.
Request your free trial of HGMD Professional here.
Have questions? Want to learn more? Check out our HGMD Professional resource hub here.
References:
The Spring 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 282,895 entries–that’s 7,179 more than the previous release.
For over 30 years, HGMD Professional has been used worldwide by researchers, clinicians, diagnostic laboratories and genetic counselors as an essential tool for the annotation of next-generation sequencing (NGS) data in routine clinical and translational research. Founded and maintained by the Institute of Medical Genetics at Cardiff University, HGMD Professional provides users with a unique resource containing expert-curated mutations all backed by peer-reviewed publications where there is evidence of clinical impact.
Whether searching for an overview of known mutations associated with a particular disease, interpreting clinical test results, looking for the likely causal mutation in a list of variants, or seeking to integrate mutation content into your custom NGS pipeline or data repository—HGMD is the defacto-standard repository for heritable mutations that can be adapted to a broad range of applications.
detailed mutation reports
new mutation entries in 2019 alone
summary reports listing all known
inherited disease mutations
HGMD is powered by a team of expert curators at Cardiff University. Data are collected weekly by a combination of manual and computerized search procedures. In excess of 250 journals are scanned for articles describing germline mutations causing human genetic disease. The required data are extracted from the original articles and augmented with the necessary supporting data.
The number of disease-associated germline mutations published per year has more than doubled in the past decade (Figure 1). As rare and novel genetic mutations continue to be uncovered, having access to the latest scientific evidence is critical for timely interpretations of next-generation sequencing (NGS) data.
View the complete HGMD Professional statistics here.
Read more about the importance of having access to the most up-to-date and comprehensive database for human disease mutations in our white paper.
HGMD Professional helps clinical testing labs analyze and annotate next-generation sequencing (NGS) data with current and trusted information. Unlike other mutation databases, HGMD mutations are all backed by peer-reviewed publications where there is evidence of clinical impact.
To get the most out of your HGMD Professional subscription, visit our Resources webpage for case studies, technical notes, and video tutorials. Or hear from Peter Stenson, manager of HGMD, in an on-demand webinar on how HGMD has empowered a generation of geneticists for precision medicine here.
Or hear from Peter Stenson, manager of HGMD, in an on-demand webinar on how HGMD has empowered a generation of geneticists for precision medicine here.
An updated version of ANNOVAR is also available.
Learn more about how ANNOVAR can be used with HGMD for variant annotation. Watch a recorded webinar featuring ANNOVAR here.
The Genome Trax™ 2020.1 is now available. Updated tracks have been released with HGMD 2020.1 content for all HGMD-related tracks. Additional major updates include TRANSFAC® release 2020.1, and PROTEOME™ release 2020.1.
For labs looking to generate clinician-grade reports for germline or somatic NGS testing, QIAGEN Clinical Insight (QCI) Interpret reproducibly translates highly complex NGS data into standardized reports using current clinical evidence from the QIAGEN Knowledge Base, which consists of over 40 public and proprietary databases, including HGMD Professional.
Click here for a free demonstration of QCI Interpret.
Unlike other mutation databases, HGMD mutations are backed by peer-reviewed publications where there is evidence of clinical impact—and the gold-standard, industry-leading resource just got better.
View the complete HGMD Professional statistics here.
When using Batch Search, the results table will now include a ClinVar column to the far right. This column will provide links to ClinVar records and list predicted classifications.
Read about the importance of having access to the most up-to-date and comprehensive database for human disease mutations in our white paper.
Learn how to take advantage of all HGMD’s features by watching our video tutorials available at our Resources Page.
New ANNOVAR databases are now available!
Learn more about how ANNOVAR can be used with HGMD for variant annotation.
Watch a recorded webinar featuring ANNOVAR here.
Genome Trax 2018.4 has updated tracks containing the 2018.4 HGMD release or all HGMD-related tracks.
Need a clinical genomic interpretation solution?
Look no further than QIAGEN Clinical Insight (QCI). Offering the highest level of interpretation transparency currently available on the market, QCI dynamically computes ACMG classification and AMP-tiering based on phenotype and clinical evidence. QCI incorporates knowledge from HGMD, CentoMD, over 30 public and proprietary databases, and over 2,000 scientific and clinical articles manually curated each month.
Kick start your year and sign-up for a free QCI demo here!
